medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 3

<< Back Next >>

Ann Hepatol 2015; 14 (3)

Does hepatitis B virus coinfection have any impact on treatment outcome in hepatitis C patients on hemodialysis?

Wahle RC, de Mello PR, Takemi EC, de Oliveira USN, da Silva FP, Melo RC, de Castro AFAC, de Souza SIS, Carvalho-Filho RJ, Benedito SAE, Gomes FML

Language: English
References: 46
Page: 317-324
PDF size: 101.69 Kb.


ABSTRACT

Background. HBV/HCV coinfection is a common finding among hemodialysis patients. However, there is scarce information concerning the impact of HBV coinfection on the response to treatment of HCV-infected patients on hemodialysis. Aim. We aimed to compare the rate of sustained virologic response (SVR) to treatment with interferon-alfa (IFN) between hemodialysis patients with HBV/HCV coinfection and those with HCV-monoinfection. Material and methods. HCV-infected patients on hemodialysis treated with IFN were included. Patients coinfected by HBV/HCV were compared to HCV-monoinfected patients, regarding clinical and biochemical features and rates of SVR. Results. One hundred and eleven patients were treated. HBV/HCV coinfection was observed in 18/111 patients (16%). Coinfected patients were younger (p = 002), had more time on dialysis (p = 0.05) and showed a tendency to present a higher prevalence of septal fibrosis (p = 0.06). The analysis by intention to treat showed SVR of 56% among coinfected patients and 18% in HCV-monoinfected patients (p = 0.004). Conclusion. In conclusion, end-stage renal disease patients with HBV/HCV coinfection exhibit higher rate of SVR to HCV treatment than HCV-monoinfected patients. It is possible that factors related to the host immune response and viral interaction could explain the better response observed among coinfected patients.


REFERENCES

  1. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; 109: S1-S99.

  2. Reddy GA, Dakshinamurthy KV, Neelaprasad P, Gangadhar T, Lakshmi V. Prevalence of HBV and HCV dual infection in patients on haemodialysis. Indian J Med Microbiol 2005; 23: 41-3.

  3. Chandra M, Khaja MN, Hussain MM, Poduri CD, Farees N, Habeeb MA, Krishnan S, et al. Prevalence of hepatitis B and hepatitis C viral infection in Indian patients with chronic renal failure. Intervirology 2004; 47: 374-6.

  4. Jain P, Nijhawan S. Occult hepatitis C infection is more common than hepatitis B infection in maintenance hemodialysis patients. World J Gastroenterol 2008; 14: 2288-9.

  5. Alashek WA, McIntyre CW, Taal MW. Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infect Dis 2012; 12:265.

  6. Liu Z, Hou J. Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection. Int J Med Sci 2006; 3: 57-62.

  7. Lin L, Verslype C, van Pelt JF, van Ranst M, Fevery J. Viral interaction and clinical implications of coinfection of hepatitis C with other hepatitis viruses. Eur J Gastroenterol Hepatol 2006; 18: 1311-9.

  8. Raimondo G, Cacciamo G, Saitta C. Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease? Ann Hepatol 2005; 4: 100-6.

  9. Shukla NB, Poles MA. Hepatitis B virus infection: co-infection with hepatitis C virus, hepatitis D virus, and human immunodeficiency virus. Clin Liver Dis 2004; 8: 445-60.

  10. Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost- Bezeaux F, Tran van Nhieu J, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28: 27-33.

  11. Pontisso P, Ruvoletto MG, Fattovich G, Chemello L, Gallorini A, Ruol A, Alberti A. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993; 105: 1529-33.

  12. Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: Epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008; 23: 512-20.

  13. Liu JY, Sheng YJ, Hu HD, Zhong Q, Wang J, Tong SW, Zhou Z, et al. The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis. Virol J 2012; 9: 186.

  14. Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 2007; 47: 598-607.

  15. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-63.

  16. Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5: 2913-21.

  17. Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat 2007; 14: 697-703.

  18. Johnson DW, Dent H, Yao Q, Tranaeus A, Huang CC, Han DS, Jha V, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant 2009; 24: 1598-603.

  19. Carbone M, Mutimer D, Neuberger J. Hepatitis C virus and nonliver solid organ transplantation. Transplantation 2013; 95: 779-86.

  20. Rostami Z, Nourbala MH, Alavian SM, Bieraghdar F, Jahani Y, Einollahi B. The impact of Hepatitis C virus infection on kidney transplantation outcomes: A systematic review of 18 observational studies: The impact of HCV on renal transplantation. Hepat Mon 2011; 11: 247-54.

  21. Elamin S, Abu-Aisha H. Prevention of hepatitis B virus and hepatitis C virus transmission in hemodialysis centers: review of current international recommendations. Arab J Nephrol Transplant 2011; 4: 35-47.

  22. Liu CJ, Liou JM, Chen DS, Chen PJ. Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. J Formos Med Assoc 2005; 104: 783-91.

  23. Sagnelli E, Coppola N, Messina V, Di Caprio D, Marrocco C, Marotta A, Onofrio M, et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 2002; 36: 1285-91.

  24. Sagnelli E, Pasquale G, Coppola N, Scarano F, Marrocco C, Scolastico C, Santantonio T, et al. Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection 2004; 32: 144-8.

  25. Sun CA, Wu DM, Lin CC, Lu SN, You SL, Wang LY, Wu MH, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003; 157: 674-82.

  26. Becker VR, Badiani RG, Lemos LB, Perez RM, Medina-Pestana JO, Lanzoni VP, Ferreira AP, et al. Factors associated with the progression of hepatic fibrosis in end-stage kidney disease patients with hepatitis C virus infection. Eur J Gastroenterol Hepatol 2009; 21: 1395-9.

  27. Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, Saitta C, Squadrito G, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-co-infected patients. Hepatology 2006; 43: 100-7.

  28. Nguyen LH, Ko S, Wong SS, Tran PS, Trinh HN, Garcia RT, Ahmed A, et al. Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. Hepatology 2011; 53: 1839-45.

  29. Lerner SM. Hepatitis C and renal transplantation. Mt Sinai J Med 2012; 79: 342-50.

  30. Fabrizi F, Aghemo A, Messa P. Hepatitis C treatment in patients with kidney disease. Kidney Int 2013; 84: 874-9.

  31. Pipili C, Cholongitas E. Management of patients with hepatitis B and C before and after liver and kidney transplantation. World J Hepatol 2014; 6: 315-25.

  32. Vallet-Pichard A, Pol S. Hepatitis C virus infection in hemodialysis patients. Clin Res Hepatol Gastroenterol 2013; 37: 340-6.

  33. Casanovas Taltavull T, BaliellasComellas C, Cruzado Garrit JM. Results of hepatitis C virus treatment in patients on hemodialysis: data from published meta-analyses in 2008. Transplant Proc 2009; 41: 2082-4.

  34. Liu CH, Kao JH. Treatment of hepatitis C virus infection with end-stage renal disease. J Gastroenterol Hepatol 2011; 26: 228-39.

  35. Fabrizi F, Dixit V, Messa P, Martin P. Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials. J Med Virol 2010; 82: 768-75.

  36. Fabrizi F, Dixit V, Martin P, Messa P. Combined antiviral therapy of hepatitis C virus in dialysis patients: metaanalysis of clinical trials. J Viral Hepat 2011; 18: 263-9.

  37. Liu CH, Huang CF, Liu CJ, Dai CY, Liang CC, Huang JF, Hung PH, et al. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med 2013; 159: 729-38.

  38. Liu CH, Liu CJ, Huang CF, Lin JW, Dai CY, Liang CC, Huang JF, et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.Gut 2015; 64: 303-11.

  39. Gordon CE, Francis J. Hepatitis C treatment in dialysis patients: is a new dawn approaching? Am J Kidney Dis 2014; 64: 178-80.

  40. Uyanikoglu A, Akyuz F, Baran B, Simsek BP, Ermis F, Demir K, Gulluoglu M, et al. Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C. Clin Res Hepatol Gastroenterol 2013; 37: 485-90.

  41. Rocha CM, Perez RM, Ferreira AP, Carvalho-Filho RJ, Pace FH, Silva IS, Pestana JO, et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 2006; 26: 305-10.

  42. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon for hepatitis C virus in hemodialysis - an individual patient meta-analysis of factors associated with sustained virological response. Clin J Am Soc Nephrol 2009; 4: 1449-58.

  43. Fucuta Pereira P da S, Uehara SN, de Mello Perez R, Feldner AC, de Melo IC, de Souza e Silva IS, Silva AE, et al. Is early virological response as predictive of the hepatitis C treatment response in dialysis patients as in non-uremic patients? Int J Infect Dis 2013; 17: e50-e53.

  44. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis 2008; 51: 263-77.

  45. Potthoff A, Jaroszewicz J, Manns MP, Wedemeyer H. Management of patients coinfected with HBV and HCV. Hot Topics Viral Hep 2010; 6: 7-15.

  46. Liu CJ. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues. J Gastroenterol Hepatol 2014; 29: 26-30.




2020     |     www.medigraphic.com